Tissue-Specific Delivery of an anti-H-ras Ribozyme Against Malignant Melanoma

Malignant melanoma is an increasingly important clinical problem in the United States, because the incidence of cutaneous malignant melanoma has been increasing significantly in recent years (1 ,2 ) Despite the use of cancer chemotherapy and immunotherapy for treatment against the advanced stages of malignant melanoma, the prognosis still remains poor (3 –5 ).